scholarly journals Correction: EGFR kinase domain mutation positive lung cancers are sensitive to intrapleural perfusion with hyperthermic chemotherapy (IPHC) complete treatment

Oncotarget ◽  
2018 ◽  
Vol 9 (81) ◽  
pp. 35285-35285
Author(s):  
Hongjuan Zhang ◽  
Cheng Zhan ◽  
Ji Ke ◽  
Zhiqiang Xue ◽  
Aiqun Zhang ◽  
...  
Keyword(s):  
Kinase Domain ◽  
Lung Cancers ◽  
Hyperthermic Chemotherapy ◽  
Complete Treatment ◽  
Kinase Domain Mutation ◽  
Egfr Kinase

scholarly journals EGFR kinase domain mutation positive lung cancers are sensitive to intrapleural perfusion with hyperthermic chemotherapy (IPHC) complete treatment

Oncotarget ◽  
2015 ◽  
Vol 7 (3) ◽  
pp. 3367-3378 ◽  
Author(s):  
Hongjuan Zhang ◽  
Cheng Zhan ◽  
Ji Ke ◽  
Zhiqiang Xue ◽  
Aiqun Zhang ◽  
...  
Keyword(s):  
Kinase Domain ◽  
Lung Cancers ◽  
Hyperthermic Chemotherapy ◽  
Complete Treatment ◽  
Kinase Domain Mutation ◽  
Egfr Kinase

scholarly journals Comparable rate of EGFR kinase domain mutation in lung adenocarcinomas from Chinese male and female never-smokers

2010 ◽  
Vol 31 (5) ◽  
pp. 647-648 ◽  
Author(s):  
Yi-hua Sun ◽  
Rong Fang ◽  
Bin Gao ◽  
Xiang-kun Han ◽  
Jun-hua Zhang ◽  
...  
Keyword(s):  
Kinase Domain ◽  
Comparable Rate ◽  
Male And Female ◽  
Kinase Domain Mutation ◽  
Never Smokers ◽  
Lung Adenocarcinomas ◽  
Chinese Male ◽  
Egfr Kinase

scholarly journals Structure–function analysis of oncogenic EGFR Kinase Domain Duplication reveals insights into activation and a potential approach for therapeutic targeting

2021 ◽  
Vol 12 (1) ◽  
Author(s):  
Zhenfang Du ◽  
Benjamin P. Brown ◽  
Soyeon Kim ◽  
Donna Ferguson ◽  
Dean C. Pavlick ◽  
...  
Keyword(s):  
Tandem Duplication ◽  
Function Analysis ◽  
Treatment Strategies ◽  
Kinase Domain ◽  
Time Resolved ◽  
Egfr Activation ◽  
Domain Duplication ◽  
Activation Mechanisms ◽  
Potential Therapeutic Intervention ◽  
Egfr Kinase

AbstractMechanistic understanding of oncogenic variants facilitates the development and optimization of treatment strategies. We recently identified in-frame, tandem duplication of EGFR exons 18 - 25, which causes EGFR Kinase Domain Duplication (EGFR-KDD). Here, we characterize the prevalence of ERBB family KDDs across multiple human cancers and evaluate the functional biochemistry of EGFR-KDD as it relates to pathogenesis and potential therapeutic intervention. We provide computational and experimental evidence that EGFR-KDD functions by forming asymmetric EGF-independent intra-molecular and EGF-dependent inter-molecular dimers. Time-resolved fluorescence microscopy and co-immunoprecipitation reveals EGFR-KDD can form ligand-dependent inter-molecular homo- and hetero-dimers/multimers. Furthermore, we show that inhibition of EGFR-KDD activity is maximally achieved by blocking both intra- and inter-molecular dimerization. Collectively, our findings define a previously unrecognized model of EGFR dimerization, providing important insights for the understanding of EGFR activation mechanisms and informing personalized treatment of patients with tumors harboring EGFR-KDD. Finally, we establish ERBB KDDs as recurrent oncogenic events in multiple cancers.

scholarly journals De novo ALK kinase domain mutations are uncommon in kinase inhibitor-naïve ALK rearranged lung cancers

Lung Cancer ◽  
2016 ◽  
Vol 99 ◽  
pp. 17-22 ◽  
Author(s):  
Antonio R. Lucena-Araujo ◽  
Jason P. Moran ◽  
Paul A. VanderLaan ◽  
Dora Dias-Santagata ◽  
Erik Folch ◽  
...  
Keyword(s):  
Kinase Inhibitor ◽  
De Novo ◽  
Kinase Domain ◽  
Lung Cancers ◽  
Kinase Domain Mutations

scholarly journals BCR-ABL1 kinase domain mutation analysis by next generation sequencing detected additional mutations in chronic myeloid leukemia patients with suboptimal response to imatinib

2021 ◽  
pp. 1-6
Author(s):  
Esther Sathya Bama Benjamin ◽  
Niveditha Ravindra ◽  
Bharathi Murugan Rajamani ◽  
Senthamizhselvi Anandan ◽  
Bagavathi Kausalya ◽  
...  
Keyword(s):  
Next Generation Sequencing ◽  
Chronic Myeloid Leukemia ◽  
Mutation Analysis ◽  
Myeloid Leukemia ◽  
Kinase Domain ◽  
Next Generation ◽  
Kinase Domain Mutation ◽  
Generation Sequencing

scholarly journals Clinical outcomes of EGFR kinase domain duplication to targeted therapies in NSCLC

2018 ◽  
Vol 144 (11) ◽  
pp. 2677-2682 ◽  
Author(s):  
Jinguang Wang ◽  
Xingya Li ◽  
Xingyang Xue ◽  
Qiuxiang Ou ◽  
Xue Wu ◽  
...  
Keyword(s):  
Clinical Outcomes ◽  
Targeted Therapies ◽  
Kinase Domain ◽  
Domain Duplication ◽  
Egfr Kinase

ERBB2 kinase domain mutation in a gastric cancer metastasis

Apmis ◽  
2005 ◽  
Vol 113 (10) ◽  
pp. 683-687 ◽  
Author(s):  
JONG WOO LEE ◽  
YOUNG HWA SOUNG ◽  
SU YOUNG KIM ◽  
WON SANG PARK ◽  
SUK WOO NAM ◽  
...  
Keyword(s):  
Gastric Cancer ◽  
Cancer Metastasis ◽  
Kinase Domain ◽  
Kinase Domain Mutation

scholarly journals Ponatinib induced improvement of cutaneous lesions associated to accelerated phase of Ph-positive chronic myeloid leukemia

2016 ◽  
Vol 8 ◽  
pp. 2016016
Author(s):  
Massimo Breccia ◽  
Gioia Colafigli ◽  
Luisa Quattrocchi ◽  
Elisabetta Abruzzese ◽  
Giuliana Alimena
Keyword(s):  
Chronic Myeloid Leukemia ◽  
Tyrosine Kinase ◽  
Tyrosine Kinase Inhibitor ◽  
Myeloid Leukemia ◽  
Kinase Inhibitor ◽  
Kinase Domain ◽  
Third Generation ◽  
Cutaneous Lesions ◽  
Advanced Phase ◽  
Kinase Domain Mutation

Ponatinib a third generation tyrosine kinase inhibitor, has been approved for all phases of disease in CML. In advanced phase, has been confirmed with a good efficacy in all type of resistance, including T315I kinase domain mutation. We here report activity of the drug in advanced phase with extramedullary localization.

Sign in / Sign up

Export Citation Format

Share Document